Collegium Pharma (COLL) Tops Q4 EPS by 62c

Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of $0.27, $0.62 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $73.4 million versus the consensus estimate of $73.86 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Sypris Solutions (SYPR) Reports Q2 Loss of $0.14
• DeFi Technologies (DEFT) PT Lowered to $1 at Benchmark Following Q2 Miss